Rankings
▼
Calendar
AKTS Q4 2024 Earnings — Aktis Oncology, Inc. Revenue & Financial Results | Market Cap Arena
AKTS
Aktis Oncology, Inc.
$1B
Q4 2024 Earnings
Healthcare
Biotechnology
Income Statement
Revenue
$933,000
Gross Profit
$933,000
100.0% margin
Operating Income
-$16M
-1675.8% margin
Net Income
-$12M
-1292.2% margin
EPS (Diluted)
$0.00
Cash Flow
Operating Cash Flow
-$13M
Free Cash Flow
-$15M
Stock-Based Comp.
$1M
Balance Sheet
Total Assets
$326M
Total Liabilities
$414M
Stockholders' Equity
-$88M
Cash & Equivalents
$37M
← FY 2024
All Quarters